Budget Impact Analysis of Olaparib for the Management of Patients with Homologous Recombination Repair (HRR)-Mutated Castration-Resistant Metastatic Prostate Cancer in Argentina

/ 2024, CIESP, Evaluación de Tecnologías Sanitarias, Publicaciones Científicas / Por

N. Espinola,C. Silvestrini,C. Colaci,D. Sugg,C. Rojas-Roque,J. Coelli and F. Augustovski. Budget Impact Analysis of Olaparib for the Management of Patients with Homologous Recombination Repair (HRR)-Mutated Castration-Resistant Metastatic Prostate Cancer in Argentina. PharmacoEconomics – Open. 2024:10.1007/s41669-024-00508-4.

Ir a la publicación